"Somatostatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 14-amino acid peptide named for its ability to inhibit pituitary GROWTH HORMONE release, also called somatotropin release-inhibiting factor. It is expressed in the central and peripheral nervous systems, the gut, and other organs. SRIF can also inhibit the release of THYROID-STIMULATING HORMONE; PROLACTIN; INSULIN; and GLUCAGON besides acting as a neurotransmitter and neuromodulator. In a number of species including humans, there is an additional form of somatostatin, SRIF-28 with a 14-amino acid extension at the N-terminal.
Descriptor ID |
D013004
|
MeSH Number(s) |
D06.472.699.327.700.875 D06.472.699.587.780 D12.644.400.400.700.875 D12.644.548.365.700.875 D12.644.548.586.780 D12.776.631.650.405.700.875
|
Concept/Terms |
Somatostatin- Somatostatin
- SRIH-14
- Somatotropin Release-Inhibiting Factor
- Somatotropin Release Inhibiting Factor
- Cyclic Somatostatin
- Somatostatin-14
- Somatostatin 14
- Somatotropin Release-Inhibiting Hormone
- Somatotropin Release Inhibiting Hormone
- Somatostatin, Cyclic
|
Below are MeSH descriptors whose meaning is more general than "Somatostatin".
Below are MeSH descriptors whose meaning is more specific than "Somatostatin".
This graph shows the total number of publications written about "Somatostatin" by people in this website by year, and whether "Somatostatin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1995 | 1 | 0 | 1 |
2008 | 0 | 1 | 1 |
2013 | 0 | 1 | 1 |
2014 | 0 | 1 | 1 |
2017 | 7 | 4 | 11 |
2018 | 7 | 5 | 12 |
2019 | 2 | 4 | 6 |
2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Somatostatin" by people in Profiles.
-
Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP-NETs: A Review of Key Issues. Oncologist. 2021 07; 26(7):e1171-e1178.
-
A metastatic tumor is no different to a viral pandemic: lessons learnt from COVID-19 may teach us to change the PRRT paradigm. Eur J Nucl Med Mol Imaging. 2020 09; 47(10):2223-2226.
-
Endocrinology in the time of COVID-19: Management of pituitary tumours. Eur J Endocrinol. 2020 Jul; 183(1):G17-G23.
-
Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors < 2 Centimeters. J Clin Endocrinol Metab. 2020 01 01; 105(1).
-
Effect of acute upper gastrointestinal bleeding manifestations at admission on the in-hospital outcomes of liver cirrhosis: hematemesis versus melena without hematemesis. Eur J Gastroenterol Hepatol. 2019 Nov; 31(11):1334-1341.
-
The GLP1R Agonist Liraglutide Reduces Hyperglucagonemia Induced by the SGLT2 Inhibitor Dapagliflozin via Somatostatin Release. Cell Rep. 2019 08 06; 28(6):1447-1454.e4.
-
Pegvisomant Improves Glucose Metabolism in Acromegaly: A Meta-Analysis of Prospective Interventional Studies. J Clin Endocrinol Metab. 2019 07 01; 104(7):2892-2902.
-
Management of postoperative chylous ascites after surgery for ovarian cancer: a single-institution experience. Updates Surg. 2019 Dec; 71(4):729-734.
-
Therapeutic sequences in patients with grade 1-2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group. Endocrine. 2019 11; 66(2):417-424.
-
The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors. Expert Rev Clin Pharmacol. 2019 Feb; 12(2):101-108.